Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Silver

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Annals of Hematology|August 15, 2024
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosisGhaith Abu-Zeinah, Albert Qin, Harinder Gill, et al.
Leukemia & Lymphoma|April 15, 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013Richard T Silver, Bercedis L Peterson, Ted P Szatrowski, et al.
Cancer Research|December 6, 2006
Characterization of murine JAK2V617F-positive myeloproliferative diseaseThomas G P Bumm, Collin Elsea, Amie S Corbin, et al.
Haematologica|July 2, 2013
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium TrialRuben A Mesa, Richard T Silver, Srdan Verstovsek, et al.
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful EngraftmentUsama Gergis, Emil Kuriakose, Tsiporah Shore, et al.
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
International Journal of Oncology|June 18, 2004
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Annals of Hematology|August 15, 2024
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosisGhaith Abu-Zeinah, Albert Qin, Harinder Gill, et al.
Leukemia & Lymphoma|April 15, 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013Richard T Silver, Bercedis L Peterson, Ted P Szatrowski, et al.
Cancer Research|December 6, 2006
Characterization of murine JAK2V617F-positive myeloproliferative diseaseThomas G P Bumm, Collin Elsea, Amie S Corbin, et al.
Haematologica|July 2, 2013
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium TrialRuben A Mesa, Richard T Silver, Srdan Verstovsek, et al.
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful EngraftmentUsama Gergis, Emil Kuriakose, Tsiporah Shore, et al.
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
International Journal of Oncology|June 18, 2004
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Pageof 9